2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size.
about
Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 MutationCirculating glioma biomarkersIDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in gliomaIDH mutations in tumorigenesis and their potential role as novel therapeutic targets.IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesIsocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma.Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.Emerging insights into the molecular and cellular basis of glioblastoma.Discordant intracellular and plasma D-2-hydroxyglutarate levels in a patient with IDH2 mutated angioimmunoblastic T-cell lymphomaPersonalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant GliomaQuantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique.What do we know about IDH1/2 mutations so far, and how do we use it?Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomasMetabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes.Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG.Circulating biomarkers of CNS tumors: an update.Liquid biopsies in patients with diffuse glioma.Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumoursCirculating biomarkers for gliomas.Emerging circulating biomarkers in glioblastoma: promises and challenges.Driver mutations of cancer epigenomes.HOT mutation screening in human glioblastomas.Mechanisms underlying the biological changes induced by isocitrate dehydrogenase-1 mutation in glioma cells.Mutant IDH1 and thrombosis in gliomas.An in vivo patient-derived model of endogenous IDH1-mutant glioma.BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles.The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells.Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.A prospective study of serum metabolites and glioma risk.Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases.MicroRNA in Glioblastoma: An Overview.In vivo Metabolic Profiles as Determined by (31)P and short TE (1)H MR-Spectroscopy : No Difference Between Patients with IDH Wildtype and IDH Mutant Gliomas.Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies.Focused Ultrasound-enabled Brain Tumor Liquid Biopsy.Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.
P2860
Q26767392-7ED33BD2-82EE-469E-BADE-BC1EF31AB237Q26830329-9766D514-F3A7-4AC4-B9B5-48E4B03F2D69Q26995506-E4C6E55C-43DE-4B30-9A1C-80F33B1C83D9Q27692015-FFA54CF6-A360-461C-B1DE-3554543944AAQ28066926-88EE0C4A-76D1-4515-82E3-413D90F56547Q33699608-481E251E-2DDD-4B59-BEB2-C1AA74374F2AQ33936179-06F8140E-E9B4-4223-B9C7-555E21890BB0Q34351124-37C47A1A-937F-4C6A-B2D1-A41F2597F53CQ35586677-1CA3836E-2666-4203-86D8-063416E9415AQ35914897-BE2EF730-C19B-4373-AF88-1A336FECD6F2Q36262067-4E37FB18-DCF8-4C81-A737-F49A125BB275Q36344709-C2B3B7B4-0742-4B42-9D83-06BB9B5E77A0Q36493858-C049CA6A-A5F5-47D0-B41F-60429805B8BEQ36558431-6D307920-EB41-4309-979F-07F9A3847AC3Q36656510-DE026077-23A7-4CA8-B43E-D453C4EB102BQ36788229-52697709-7A1A-4485-9AAC-1478F72A432BQ36865995-F82D1F05-62AA-40DA-AE43-66F1C4878F4FQ37190344-9D660D68-BDFB-4699-945C-AB6DD85B6CE5Q37240701-208A982D-B9D5-45E2-B261-3720633CA48DQ37485784-10AB682C-0E04-47EE-943E-DD6CDA7A11B8Q38095109-8D6F42FE-5241-4CDE-A9E0-5368306DB01DQ38365590-7143B139-8133-4E42-871C-41FE885E8119Q38375735-440AF17B-DCE1-459E-BC99-BA541D8F0D8DQ38586617-A39A7933-0D76-403F-BD1E-0EBED3AF2FACQ38591062-CE47CBFC-0A45-4662-9294-749C963B675EQ38639828-4B53F9A4-6A53-4729-B329-02CE65B18120Q38747962-FDB1B5CC-B502-4509-AA60-3FF05D97F2F2Q39024621-830A511F-A889-4187-BEEE-221BBA4205BEQ39355644-5C9AD1B6-F4D5-426E-AF48-8887735E1C27Q39429029-2E9058CD-5030-4D84-8208-33DF95441A0BQ40126434-520564D0-D2C6-453D-AA7D-9FFB6BE91F42Q41859976-5A707829-4C56-4331-8D06-A68A3E6350CFQ42246513-C4476F9A-8F30-44B7-9B4F-1AF3C698DBA8Q42378435-5C055D8D-03C9-43E1-BE4E-884C170E051FQ46104308-28DD3979-AFBF-4E86-B703-C3013536EE10Q47142132-A30AD404-3EEF-47F7-AF13-EBAE539F72F8Q47853442-10968ADF-C88C-458E-8277-237701D5C865Q50033966-01FCD8F4-D60C-41C6-A746-3B0AC63C2161Q52560196-11CBC2D6-4670-438C-8EA1-06CAE3F8648CQ52584624-15F4069C-D9F0-494C-85B3-E889D981BECD
P2860
2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
2-Hydroxyglutarate concentrati ...... mutation status or tumor size.
@en
2-Hydroxyglutarate concentrati ...... mutation status or tumor size.
@nl
type
label
2-Hydroxyglutarate concentrati ...... mutation status or tumor size.
@en
2-Hydroxyglutarate concentrati ...... mutation status or tumor size.
@nl
prefLabel
2-Hydroxyglutarate concentrati ...... mutation status or tumor size.
@en
2-Hydroxyglutarate concentrati ...... mutation status or tumor size.
@nl
P2093
P50
P356
P1476
2-Hydroxyglutarate concentrati ...... mutation status or tumor size.
@en
P2093
Christian Hartmann
Claus-Dieter Langhans
German Glioma Network
Jörg C Tonn
Jürgen G Okun
Matthias Simon
P304
P356
10.1002/IJC.26425
P577
2011-11-02T00:00:00Z